The Liberia Crusaders for Peace, in collaboration with the Partnership for Research on Ebola Vaccines in Liberia (PREVIAL), conducted a one-day social mobilization refresher training for communicators on the trial vaccines in support of Ebola prevention in the country.
The training, which was conducted Thursday March 5, at the Liberia Crusaders for Peace headquarters in Monrovia, brought together over seventy participants from districts in Montserrado County.
LCP’s Executive Secretary Sunday Wiah, Jr. said that the objective of the training was to educate the participants on the ongoing vaccine study to help eradicate the killer disease.
He said it provided better understanding on social mobilization that will guide them as they go about creating awareness on the vaccines in the districts and communities.
He urged the participants to learn, listen and act to spread the right message and to dispel the myth that the vaccines kill or infect people with the Ebola virus.
At the same time Liberia Cultural Ambassador, Julie Endee, told the participants to be very smart while carrying out awareness in their districts and communities.
She disclosed that following the vaccine study, Liberia stands to benefit from infrastructural development, including health facilities, doctors and scientists to help the country move forward.
She encouraged Liberians to be a part of the process by taking the vaccines which will prevent them from getting Ebola.
“It’s very important to take the vaccines because it will protect you against EVD like polio and other vaccines we normally take in our country. This vaccine is not for children, Ebola survivors and pregnant women,” the LCP Boss cautioned.
At the workshop several participants got the clarification that the trial vaccines are not in the country to kill Liberians, but rather to serve as a protection against the Ebola virus.
The participants thanked LCP for the workshop and promised to encourage others in their communities to participate in the study.
The current vaccine study began in October 2014 led by a Liberia-US-clinical research partnership, including the US National Institute of Allergy and Infectious Diseases (NIAID).